The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and substantial returns is undeniable, the linked risks are also notable. Many of these p